Salminen WF, Wiles ME, Stevens RE. Streamlining nonclinical drug development using the FDA 505 (b)(2) new drug application regulatory pathway. Drug Dis Today. 2019;24(1):46–56.

Article  Google Scholar 

Rathee P, et al. 505 (b)(2)-A smart pathway to differentiate from competitive, low margin environment of generics. J Gener Med. 2021;17(4):183–94.

Article  Google Scholar 

Sakai S, DiMasi JA, Getz KA. Analysis of review times for recent 505 (b)(2) applications. Ther Innov Regul Sci. 2017;51(5):651–6.

Article  PubMed  Google Scholar 

US Food and Drug Administration (FDA). Center for Drug Evaluation and Research (CDER). Draft guidance for industry applications covered by section 505 (b)(2). Published October 1999; Available from: https://www.fda.gov/downloads/Drugs/Guidances/ucm079345.pdf

Prue JC, Mayorga AJ. The 505 (b)(2) new drug application. Drug Inf J: DIJ/Drug Inf Association. 2007;41:349–52.

Article  Google Scholar 

Chen, J., et al., Utilizing 505 (b)(2) Regulatory Pathway for New Drug Applications: An Overview on the Advanced Formulation Approach and Challenges. Drug Repurposing-Advances, Scopes and Opportunities in Drug Discovery, 2023.

Devi, S.K., et al., Regulatory landscape and challenges in CAR-T cell therapy development in the US, EU, Japan, and India. European Journal of Pharmaceutics and Biopharmaceutics, 2024: p. 114361.

FDA, U. Expedited Programs for Serious Conditions | Drugs and Biologics. 2014; Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/expedited-programs-serious-conditions-drugs-and-biologics.

Search Orphan Drug Designations and Approvals. Available from: https://www.accessdata.fda.gov/scripts/opdlisting/oopd/.

Dushantrao SC, Joga R, Kumar S. Vosoritide, a miracle drug, covering unmet need in achondroplasia: a regulatory update. Intractable & Rare Dis Res. 2023;12(4):257–61.

Article  Google Scholar 

FDA, U. Federal Register / Vol. 78, No. 113 / Wednesday, June 12, 2013 / Rules and Regulations. 2013; Available from: https://www.govinfo.gov/content/pkg/FR-2013-06-12/pdf/2013-13930.pdf.

FDA, U. Nephroscan label. 2022; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214993s000lbl.pdf#:~:text=NEPHROSCAN%20%28kit%20for%20the%20preparation%20of%20technetium%20Tc,injection%29%2C%20for%20intravenous%20use%20Initial%20U.S.%20Approval%3A%201982.

FDA, U. Pedmark label. 2022; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/212937s000lbl.pdf.

FDA, U. Sezaby label. 2022; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215910s000lbl.pdf.

FDA, U. Austedo Xr label. 2024; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216354s006lbl.pdf.

FDA, U. Hepzato label. 2023; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/201848s000lbl.pdf.

FDA, U. Cuvrior label. 2022; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215760s000lbl.pdf.

FDA, U. Pheburane label. 2022; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216513s000lbl.pdf.

FDA, U. Lumryz label. 2023; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214755Orig1s000lbl.pdf.

2024. Libervant label. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218623s000lbl.pdf.

FDA, U. Verkazia label. 2021; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214965s000lbl.pdf.

FDA, U. RECORLEV label. 2023; Available from: https://www.recorlev.com/full-prescribing-information.pdf.

FDA, U. Valtoco label. 2021; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211635s003lbl.pdf.

FDA, U. PROCYSBI label. 2020; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213491s000lbl.pdf.

FDA, U. Mycapssa label. 2020; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208232s000lbl.pdf.

FDA, U. Alkindi Sprinkle label. 2020; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213876s000lbl.pdf.

FDA, U. Bronchitol label. 2020; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202049s000lbl.pdf.

FDA, U. Sutab label. 2022; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213135s003lbl.pdf.

FDA, U. Thiola Ec label. 2021; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211843s002lbl.pdf.

FDA, U. Ga-68-Dotatoc label. 2019; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210828s000lbl.pdf.

FDA, U. Ozobax label. 2019; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208193s000lbl.pdf.

FDA, U. Dexamethasone label. 2019; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211379s000lbl.pdf.

FDA, U. Exservanlabel. 2019; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212640s000lbl.pdf.

FDA, U. Genosyl label. 2019; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202860s000lbl.pdf.

FDA, U. Tissueblue label. 2019; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209569s000lbl.pdf.

FDA, U. Amvuttra. 2022; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215515s000lbl.pdf.

FDA, U. Vuity. 2021; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214028s000lbl.pdf.

FDA, U. Avaclyr. 2019; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/202408s001lbl.pdf.

FDA, U. Hemady. 2019; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211379s000lbl.pdf.

USFDA. Priority review. Available from: https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/priority-review.

FDA, U. CDER Priority Drug and Biologic Approvals. Available from: https://www.fda.gov/drugs/nda-and-bla-approvals/priority-nda-and-bla-approvals.

FDA, U. Dolutegravirlabel. 2023; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/pepfar/215319PI.pdf.

FDA, U. Brixad label. 2023; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210136Orig1s000lbl.pdf.

FDA, U. Lodoco label. 2023; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215727s000lbl.pdf.

FDA, U. Abacavir, Dolutegravir & Lamivudine label. 2022; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205551s010lbl.pdf.

FDA, U. Melphalan Hydrochloride injection. 2023; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217110s000lbl.pdf.

FDA, U. Darunavir & Ritonavir label. 2023; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/pepfar/209847PI.pdf.

FDA, U. Naloxone label. 2022; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215457s000lbl.pdf.

FDA, U. Midazolam label. 2022; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216359s000lbl.pdf.

FDA, U. Auvelity label. 2024; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215430s008lbl.pdf.

USFDA. Accelerated approval. Available from: https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/accelerated-approval.

FDA, U. CDER Drug and Biologic Accelerated Approvals Based on a Surrogate Endpoints As of June 30, 2024. Available from: https://www.fda.gov/media/151146/download?attachment.

FDA, U. Tarpeyo label. 2021; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215935s000lbl.pdf.

FDA, U. Lampit label. 2020; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213464s000lbl.pdf.

FDA, U. Romidepsin label. 2020; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208574Orig2lbl.pdf.

FDA, U. Qualified Infectious Disease Product Designation Questions and Answers. 2021; Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/qualified-infectious-disease-product-designation-questions-and-answers.

FDA, U. Voquezna Triple Pak label. 2022; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215152s000,215153s000lbl.pdf.

FDA, U. Xacduro label. 2023; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216974Orig1s000Correctedlbl.pdf.

FDA, U. Breakthrough designation. Available from: https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy.

FDA, U. CDER Breakthrough Therapy Designation Approvals. Available from: https://www.fda.gov/media/95302/download.

FDA, U. Jelmyto label. 2024; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211728s010lbl.pdf.

FDA, U. Artesunate label. 2020; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213036s000lbl.pdf.

FDA, U. Zynrelef label. 2021; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211988s000lbl.pdf.

FDA, U. FYARRO label. 2021; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213312lbl.pdf.

FDA, Iwilfin label. 2023; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215500s000lbl.pdf.

FDA, U. Fast Track. Available from: https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/fast-track.

FDA, U. CDER Fast Track Designation Approvals. Available from: https://www.fda.gov/media/161333/download?attachment.

FDA, U. Fintepla label. 2022; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/212102s003lbl.pdf.

FDA, U. DOJOLVI label. 2020; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213687s003lbl.pdf.

FDA, U. Tralement label. 2020; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209376s000lbl.pdf.

FDA, U. Detectnet label. 2020; Available from: https://www.accessdata.fda.gov/Drugsatfda_Docs/Label/2020/213227s000lbl.Pdf.

FDA, U. Xaciato label 2021; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215650s000lbl.pdf.

FDA, U. Hyftor label. 2022; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213478s000lbl.pdf.

FDA, U. Igalmi label. 2021; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215650s000lbl.pdf.

FDA, U. Rextovy label. 2023; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208969s000lbl.pdf.

FDA, U. Opvee label. 2023; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217470Orig1s000.pdf.

FDA, U. Rivive label. 2023; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/217722Orig1s000ltr.pdf.

FDA, U. Elcys label. 2019; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210660lbl.pdf.

FDA, U. Nayzilam label. 2019; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211321s000lbl.pdf.

FDA, U. Talicia label. 2019; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213004lbl.pdf.

FDA, U. Selenious Acid label. 2019; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209379s000lbl.pdf.

Pugatch MP. Intellectual property, data exclusivity, innovation and market access. In: Negotiating Health. Routledge; 2012. p. 97–131.

Google Scholar 

Ragavan S. Data exclusivity: a tool to sustain market monopoly. Jindal Global Law Rev. 2017;8:241–60.

Article  Google Scholar 

Rome BN, Lee CC, Kesselheim AS. Market exclusivity length for drugs with new generic or biosimilar competition, 2012–2018. Clin Pharmacol Ther. 2021;109(2):367–71.

Article  PubMed  Google Scholar 

M.Lassman, S. Submarine Exclusivity: Unseen Risk for 505(b)(2) Applications. 2019.

FDA, U. General advice. NDA 206406. Veloxis Pharmaceuticals, Inc. 2015; Available from:https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206406Orig1s000AdminCorres.pdf. Page 64 0f 285.

FDA, U. CDER exclusivity board. MorphaBond-Exclusivity. 2016; Available from: https://www.fda.gov/media/103075/download.

FDA, U. CDER Exclusivity board. Adzenys-ER-Exclusivity. 2017; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/204325Orig1s000Admincorres.pdf. Page 10 of 85.

FDA., U. Summary review of Envarsus XR. 2015; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206406Orig1s000SumR.pdf.

RESEARCH., C.F.D.E.A. ADMINISTRATIVE and CORRESPONDENCE DOCUMENTS OF ADZENYS ER. 2017; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/204325Orig1s000Admincorres.pdf.

COLUMBIA, U.S.D.C.F.T.D.O. Otsuka Pharmaceutical CO., LTD., et al., VS United States Department of Health and Human Services, et al., . 2015; Available from: https://ecf.dcd.uscourts.gov/cgi-bin/show_public_doc?2015cv1688-39.

CENTER FOR DRUG EVALUATION AND RESEARCH. ADMINISTRATIVE and CORRESPONDENCE DOCUMENTS OF GANZYK-RTU. 2017; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209347Orig1s000Admincorres.pdf.

FDA, U. Tentative 505 (b) (2) approval of Liquidia's Yutrepia (treprostinil inhalation powder) Oral inhalation. 2020; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/213005Orig1s000TAltr.pdf.

DELAWARE, U.S.D.C.F.T.D.O. UNITED THERAPEUTICS CORPORATION, VS LIQUIDIA TECHNOLOGIES, INC., . 2020; Available from: https://www.govinfo.gov/content/pkg/USCOURTS-ded-1_20-cv-00755/pdf/USCOURTS-ded-1_20-cv-00755-0.pdf.

DELAWARE, U.S.D.C.F.T.D.O. UNITED THERAPEUTICS CORPORATION, Plaintiff, V. LIQUIDIA TECHNOLOGIES, INC., Defendant. . 2023; Available from: https://www.